Advisory Research’s Seres Therapeutics MCRB Stock Holding History

Advisory Research’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,678	Closed	-$417K	–	465
2023 Q1	$417K	Buy	+3,678	New	+$398K	0.07%	263

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Advisory Research's MCRB Position: Q2 2023 in Review

Advisory Research sold out of Seres Therapeutics (MCRB) in Q2 2023, closing a stake of 3,678 shares — an estimated $417K sold.

Advisory Research first reported a position in MCRB in Q1 2023 and held it in 1 quarter. The position peaked at $417K in Q1 2023. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

Advisory Research reported no remaining Seres Therapeutics position as of Q2 2023 after selling out during the quarter.
Advisory Research sold 3,678 Seres Therapeutics shares in Q2 2023, an estimated $417K.
Advisory Research first reported a position in Seres Therapeutics in Q1 2023 and held it in 1 quarter.
Advisory Research's Seres Therapeutics position peaked at $417K in Q1 2023.
137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.